Trial Profile
GCC 0319: Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Mar 2020
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 08 Apr 2014 Primary endpoint changed from Maximally tolerated dose to Overall response as reported by ClinicalTrials.gov
- 01 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jul 2009 New trial record